Xlife Sciences AG Stock price BOERSE MUENCHEN
Equities
XLS
CH0461929603
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
41.8 EUR | -0.48% | -7.52% | -3.69% |
Feb. 05 | Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership | MT |
Dec. 20 | Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection | MT |
Sales 2023 * | 800K 887K 820K | Sales 2024 * | 800K 887K 820K | Capitalization | 258M 286M 264M |
---|---|---|---|---|---|
Net income 2023 * | -4M -4.44M -4.1M | Net income 2024 * | -4M -4.44M -4.1M | EV / Sales 2023 * | 402 x |
Net Debt 2023 * | 63.9M 70.86M 65.51M | Net Debt 2024 * | 65.2M 72.31M 66.84M | EV / Sales 2024 * | 404 x |
P/E ratio 2023 * |
-62.8
x | P/E ratio 2024 * |
-68.5
x | Employees | 13 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 47.79% |
1 day | -0.48% | ||
Current month | -3.69% | ||
Current year | -3.69% |
Managers | Title | Age | Since |
---|---|---|---|
Oliver Baumann
CEO | Chief Executive Officer | - | 19-06-30 |
Carl von Halem
DFI | Director of Finance/CFO | - | 21-11-30 |
Alexander Zink
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Christian Faber
CMP | Compliance Officer | - | 19-09-11 |
Mark Müller
BRD | Director/Board Member | - | 18-10-24 |
Oliver Baumann
CEO | Chief Executive Officer | - | 19-06-30 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.73% | 45.97B | |
+52.78% | 43.93B | |
+9.64% | 42.34B | |
-8.59% | 28.27B | |
+16.95% | 27.18B | |
-20.28% | 19.44B | |
+13.79% | 13.83B | |
+31.78% | 12.4B | |
+8.44% | 11.45B |
- Stock
- Equities
- Stock Xlife Sciences AG
- Stock Xlife Sciences AG - BOERSE MUENCHEN